Analyst Price Targets — CDNA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 9:01 pm | Sung Ji Nam | BTIG | $26.00 | $18.46 | StreetInsider | CareDx, Inc (CDNA) PT Raised to $26 at BTIG |
| January 6, 2026 12:43 pm | — | Craig-Hallum | $26.00 | $19.81 | TheFly | CareDx downgraded to Hold from Buy at Craig-Hallum |
| December 15, 2025 11:25 am | Brandon Couillard | Wells Fargo | $18.00 | $20.57 | TheFly | CareDx price target raised to $18 from $14 at Wells Fargo |
| March 3, 2025 11:13 am | — | H.C. Wainwright | $25.00 | $21.13 | TheFly | CareDx price target lowered to $25 from $26 at H.C. Wainwright |
| November 5, 2024 10:13 am | Sung Ji Nam | BTIG | $35.00 | $22.90 | StreetInsider | CareDx, Inc (CDNA) PT Lowered to $35 at BTIG |
| August 19, 2024 7:50 am | Mark Massaro | BTIG | $40.00 | $33.00 | TheFly | CareDx upgraded to Buy from Neutral at BTIG |
| August 16, 2024 3:05 pm | Bill Bonello | Craig-Hallum | $40.00 | $32.98 | TheFly | CareDx price target raised to $40 from $32 at Craig-Hallum |
| August 1, 2024 8:23 am | Bill Bonello | Craig-Hallum | $32.00 | $19.99 | TheFly | CareDx price target raised to $32 from $22 at Craig-Hallum |
| April 17, 2024 2:04 pm | Mason Carrico | Stephens | $15.00 | $8.29 | StreetInsider | Stephens Reiterates Overweight Rating on CareDx, Inc (CDNA) |
| February 6, 2023 9:50 am | — | Goldman Sachs | $29.00 | $16.26 | Benzinga | Goldman Sachs Maintains Buy on CareDx, Lowers Price Target to $29 |
Latest News for CDNA
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On February 24, 2026, as an inducement material to acceptance of employment…
CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CareDx (CDNA) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.18 per share a year ago.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CDNA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.